Larvol Delta - Efficacy-and-safety-of-adjuvant-CDK46-inhibitors-in-hormone-receptorpositive-HER2negative-early-breast-cancer-Updated-evidence-from-a-systematic-review-and-metaanalysis

Kisqali (ribociclib) - Novartis

Ibrance (palbociclib) - Pfizer

Verzenio (abemaciclib) - Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42593362

Afef Khanfir; Wala Ben Kridis

Aug 14, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next